Executive Summary
Adimanebart is a first-in-class MuSK agonist antibody being developed in congenital myasthenic syndromes, ALS, and SMA with 3+ indications.
Adimanebart
MuSK · Antibody (MuSK agonist antibody)
Mechanism of Action[Corp '26 S20]
TypeMuSK agonist antibody
DescriptionAgonist antibody that activates MuSK at the neuromuscular junction to strengthen nerve-muscle connections
DifferentiationFirst-in-class MuSK agonist approach
Indications: CMS (Congenital Myasthenic Syndromes)ALSSMA
Target Biology[Corp '26 S20]
MuSK is a critical receptor at the neuromuscular junction that helps organize and maintain the connection between nerves and muscles. By activating (agonizing) MuSK, adimanebart aims to strengthen this connection in diseases where it is impaired.
Clinical Data
No clinical trial data available.
Investment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Market Opportunity
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| CMS registrational study initiation | 3Q 2026 | critical | First-in-class MuSK agonist entering registrational. Positive PoC data in CMS from Phase 1b. | — |
| ALS Phase 2a PoC readout | 1H 2026 | high | Proof-of-concept in ALS. MuSK biology could strengthen neuromuscular junction. | — |
| SMA PoC study | Ongoing (started end 2025) | medium | Exploring MuSK agonism in spinal muscular atrophy. | — |